Published • loading... • Updated
Annovis Bio Publishes Phase 2/3 Alzheimer’s Trial Results
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Annovis Bio Publishes Phase 2/3 Alzheimer’s Trial Results
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) recently published results from a Phase 2/3 clinical trial evaluating its investigational drug buntanetap in patients with mild to moderate Alzheimer’s disease, reporting cognitive improvements in certain biomarker-positive patients and continued advancement of a late-stage study. The randomized, double-blind, placebo-controlled trial enrolled 351 patients who received buntanetap at doses of 7.5 mg, 1…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
